Fennec Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:FENC) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 58.92 M44.95 M46.4 M44.88 M49.26 M Total liabilities 64.09 M50.82 M52.28 M52.34 M53.75 M Total equity 5.17 M5.87 M5.88 M7.46 M4.49 M Total liabilities & shareholders' equities 58.92 M44.95 M46.4 M44.88 M49.26 M Total debt ————— Net debt —————

Notizie

Certara, Inc. (CERT) Q4 Earnings Lag Estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)

City of Hope to study PEDMARK for hearing protection in testicular cancer

Fennec’s pediatric hearing protection drug shows positive results in Japan

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals repays all outstanding convertible notes

Fennec Pharmaceuticals raises $5 million in non-brokered offering

Fennec Pharmaceuticals raises $40.25 million through public offering

Fennec Pharmaceuticals plans $5 million share offering to existing investors

Fennec Pharmaceuticals prices $35 million public offering

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates